|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 11400 Rockville Pike |
Address2 |
|
| City | Rockville |
State | MD |
Zip Code | 20852 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104864-12
|
||||||||
|
6. House ID# 440290001
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kelly Corredor |
Date | 4/15/2026 8:09:07 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline
Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026.
Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care.
Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements.
ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment.
Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options.
Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder.
Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC).
In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times.
Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline
Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026.
Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care.
Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements.
ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment.
Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options.
Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder.
Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC).
In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times.
Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline
Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026.
Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care.
Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements.
ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment.
Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options.
Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder.
Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC).
In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times.
Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline
Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026.
Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care.
Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements.
ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment.
Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options.
Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder.
Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC).
In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times.
Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline
Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026.
Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care.
Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements.
ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment.
Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options.
Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder.
Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC).
In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times.
Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline
Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026.
Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care.
Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements.
ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment.
Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options.
Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder.
Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC).
In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times.
Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |